Instructions for Use, Warnings and Cautions in Nigerian Device Labelling
Updated: 2026-11-12 · GRZAN Regulatory Team · Verification date 2026-10-20
1. Key takeaways
Nigeria’s requirements for instructions and warnings are distributed across three layers: Regulation 24 of the Regulations (instructions for use), Regulation 25 (warnings and cautions) and Regulation 26 (displayed information must not mislead and must not be removed, altered or defaced); guideline VBM-R&RA-GDL-001-01 §7.3.1–§7.3.13 then sets out a 13-item list of what the instructions for use should contain, which serves as the direct checklist for writing an IFU.
The test for how much to write is not page count but three correspondences: correspondence with the intended use, correspondence with the risk classification, and consistency with the other information on the label. Regulation 26(2) adds a further red line — information on the label must not be removed, altered or defaced — which extends the duty into distribution and end use. A technically perfect IFU can still fail review if its performance statements drift from the label claims, so the three documents should be drafted together and reviewed as one package rather than sequentially by separate teams.
2. Legal basis
| Instrument | Reference number | Date | Provisions |
|---|---|---|---|
| NAFDAC Medical Devices and Related Products (Registration, Labelling and Advertisement) Regulations, 2024 | S.I. No. 42 of 2024 | 16 October 2024 | Regulation 24 (instructions for use), Regulation 25 (warnings and cautions), Regulation 26 (displayed information; no misleading, no removal or alteration), Regulation 16 (labelling information), Regulation 48 (penalties) |
| NAFDAC Guidelines for Registration of Medical Devices Including In Vitro Diagnostics (IVDs) and Related Products | VBM-R&RA-GDL-001-01 | Effective 10 April 2025 | §7.3.1–§7.3.13 (list of IFU contents) |
| NAFDAC Guidelines for Registration of Medical Devices (Imported and Locally Manufactured) in Nigeria | R&R-GDL-008-02 | Effective 3 May 2024 | §10.1–§10.2 (minimum labelling requirements) |
| NAFDAC Medical Devices GMP Guidelines 2024 | DER-GDL-025-00 | Effective 11 November 2024 | §12.1 (labelling scope includes IFU and maintenance manuals), §12.10 (sterile device labelling) |
3. Expert insights
Insight one: the 13-item IFU list is minimum content, not recommended content. VBM-R&RA-GDL-001-01 §7.3.1–§7.3.13 lists item by item the information the instructions for use should contain. In practice we use it as a checklist: every item must be locatable at a specific page in the IFU. A missing item is not a matter of insufficient detail but of a non-conforming dossier, which proceeds directly into the compliance query stage — and a compliance query stops the clock (R&R-GDL-008-02 §12.8 / VBM-R&RA-GDL-001-01 §11.8), with the application automatically closed if unanswered for 90 days / 90 working days. Because the consequence of one missing item is a stopped clock, the page-mapping exercise should be done before submission, not during review.
Insight two: the adequate warnings standard of Regulation 25 is a dynamic standard linked to risk classification. Regulation 25 requires the label to state adequate warnings and cautions. Adequacy has an objective reference in the Nigerian framework: the higher the classification (Class C, Class D) and the greater the invasiveness (First Schedule, Rules 5–7), the more specific the warning content should be. Sterile devices must additionally be labelled per GMP §12.10, with no resterilisation and no reuse. A warning block copied unchanged across a whole catalogue therefore cannot be adequate for all products in it; warnings should be written per product family against its classification and invasiveness profile.
Insight three: instructions for small packages may accompany the device, but cannot be omitted. Where the outer packaging is too small to carry the complete instructions for use, the practical route is a package insert accompanying the device, rather than omitting content. We discussed the same fallback logic in article 23 — the carrier of the information may change; the content may not be reduced. This is worth restating because artwork teams under space pressure are often tempted to trim the insert text; the Regulations permit relocation, not abbreviation of substance.
Insight four: Regulation 26 extends the duty into distribution and the end user. Regulation 26(1): displayed information must not be misleading, and misleading information constitutes an offence, falling directly under the Regulation 48 penalties (natural persons: imprisonment of up to 1 year, or a fine of up to ₦800,000, or both; corporate bodies: up to ₦5,000,000). Regulation 26(2): no person may remove, alter or deface label information. This means importers, distributors and even end-use facilities are within scope, and the agreements with authorised representatives and local importers must include this obligation. The penalty figures make clear that label integrity is treated as a criminal-law matter, not a documentation preference.
Insight five: the IFU and advertising are two separate texts; do not mix them. The instructions for use are part of the labelling system; advertising requires a separate advertisement permit (Regulation 32), and registration does not equal an advertisement permit (Regulation 11.3 / §12.3). Copying performance statements from the IFU into promotional material triggers the claim restrictions of Regulations 41 and 42 — especially the words fast / immediate / instant / rapid, for which Regulation 51 gives quantified definitions: Fast = the claimed effect appears within 30 minutes; Immediate / Instant = within 10 seconds. Using these words requires corresponding performance study support, so the translation step from IFU to marketing copy is where most violations are born.
4. Practical recommendations
- Write the IFU against the 13-item checklist item by item, noting the corresponding page number for each item to ease review location.
- Scale warnings and cautions by classification and invasiveness, with extra weight for Class C and Class D and implanted devices.
- Use a package insert for small-size packaging with no reduction of content.
- Run a three-way consistency check across IFU, label and advertising text, especially performance statements and figures.
- Insert the Regulation 26(2) obligation into importer and distributor agreements (no removal, alteration or defacement of labels).
- Review advertising text separately, and prepare performance study evidence before using words such as fast, immediate, instant or rapid.
Each recommendation maps to a document the reviewer or inspector will eventually read. Preparing them together keeps the story consistent and removes the most common cause of stopped clocks in this area, which is inconsistency between documents rather than absence of content.
5. Verification checklist
- □ The IFU covers all 13 items of §7.3.1–§7.3.13 with page numbers noted.
- □ The label states adequate warnings and cautions (Regulation 25).
- □ Small-package devices use a package insert rather than reduced content.
- □ Displayed information has been checked as not misleading (Regulation 26(1)).
- □ Importer and distributor agreements include the duty not to remove, alter or deface labels (Regulation 26(2)).
- □ Advertising text and IFU performance statements have been reviewed separately, with quantified words supported by studies.
Regulatory information verified as of 29 October 2026. All content cited above was checked against the official Regulations (S.I. No. 42 of 2024, Regulations 16, 24, 25, 26, 41, 48, 51), VBM-R&RA-GDL-001-01 (§7.3.1–§7.3.13), R&R-GDL-008-02 (§10.1–§10.2) and the GMP guideline (DER-GDL-025-00 §12.1, §12.10).
GRZAN supports manufacturers entering the Nigerian market with registration documentation and conformity files, including classification determination, registration pathway selection, technical documentation to the IMDRF ToC, GMP and foreign inspection readiness, advertisement permits, vigilance and PMS reporting, change management and renewal. Local resources in Nigeria cover licensed import entities and authorised representative services, NAPAMS online submission, dossier screening permit liaison, import permits, sample delivery and laboratory analysis support. Contact: hito.lin@grzan.cn; website www.grzan.cn.
Disclaimer
Prepared by GRZAN from publicly available regulation. It is provided for general information only and does not constitute legal advice. Legislation and official fees are subject to change by the competent authority.
About GRZAN
GRZAN (Global Regulatory Zone Access Navigator) — the global market-access navigator for medical devices and IVDs.
GRZAN is a specialist consultancy for medical device and IVD market access, providing end-to-end regulatory solutions across the product lifecycle and making international market entry simpler and faster.
Key figures. More than 25 wholly owned subsidiaries worldwide covering 50+ countries and regions; chosen by 100+ listed and leading Chinese device manufacturers, with 4,000+ successful cases; 12+ years in the sector and 200+ regulatory training sessions and seminars delivered.
What we do. Global market access: multi-country registration programmes, technical documentation, regulatory advice. Clinical evidence: clinical evaluation reports (CER), usability studies, overseas clinical investigations. Quality systems: ISO 13485, MDSAP, FDA QMSR and BGMP implementation and audit readiness. Authorised representative and licence-holder services across Southeast Asia, Latin America, the Middle East, Africa, Europe and North America.
Why GRZAN. A real operating entity, with the certificate held by the manufacturer: our direct overseas subsidiaries act as the compliant local holder, so the regulatory relationship stays clear and you keep control rather than being tied to a distributor. Direct access to the team: no time-zone gap, no language barrier, no cultural gap. Review points anticipated: we know what FDA 510(k), EU MDR, Southeast Asian, Latin American and Middle Eastern reviewers look for, which shortens timelines and reduces deficiency letters. Pathway planning: pre-decision analysis and risk assessment before you commit.
Every engagement rests on three commitments: efficiency through pre-submission review, certainty through a clear pathway, and stability through a licence-holder that stays in place.
Take your devices global with GRZAN
We work with manufacturers worldwide to open new markets with a clear regulatory pathway.
Contact us